These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 23728850)
1. The effect of 5α-reductase inhibitors on prostate growth in men receiving testosterone replacement therapy: a systematic review and meta-analysis. Cui Y; Zong H; Yang C; Yan H; Zhang Y Int Urol Nephrol; 2013 Aug; 45(4):979-87. PubMed ID: 23728850 [TBL] [Abstract][Full Text] [Related]
2. Dutasteride reduces prostate size and prostate specific antigen in older hypogonadal men with benign prostatic hyperplasia undergoing testosterone replacement therapy. Page ST; Hirano L; Gilchriest J; Dighe M; Amory JK; Marck BT; Matsumoto AM J Urol; 2011 Jul; 186(1):191-7. PubMed ID: 21575967 [TBL] [Abstract][Full Text] [Related]
3. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Cui Y; Zong H; Yan H; Zhang Y Prostate Cancer Prostatic Dis; 2014 Jun; 17(2):132-43. PubMed ID: 24445948 [TBL] [Abstract][Full Text] [Related]
4. 5α-Reductase inhibitor is less effective in men with small prostate volume and low serum prostatic specific antigen level. Lin VC; Liao CH; Wang CC; Kuo HC J Formos Med Assoc; 2015 Sep; 114(9):865-71. PubMed ID: 24064231 [TBL] [Abstract][Full Text] [Related]
5. The effect of androgen-replacement therapy on prostate growth: a systematic review and meta-analysis. Cui Y; Zhang Y Eur Urol; 2013 Nov; 64(5):811-22. PubMed ID: 23567065 [TBL] [Abstract][Full Text] [Related]
6. Combination of α-blocker and 5α-reductase inhibitor for treatment of benign prostatic hyperplasia. Kang D; Hu C; Fu Y; Wang D Clin Invest Med; 2017 Oct; 40(5):E200-E210. PubMed ID: 29061225 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis. Kim JH; Baek MJ; Sun HY; Lee B; Li S; Khandwala Y; Del Giudice F; Chung BI PLoS One; 2018; 13(10):e0203479. PubMed ID: 30281615 [TBL] [Abstract][Full Text] [Related]
8. An updated systematic review and meta-analysis of the effects of testosterone replacement therapy on erectile function and prostate. Xu Z; Chen X; Zhou H; Ren C; Wang Q; Pan Y; Liu L; Liu X Front Endocrinol (Lausanne); 2024; 15():1335146. PubMed ID: 38344665 [TBL] [Abstract][Full Text] [Related]
9. Dutasteride in men receiving testosterone therapy: a randomised, double-blind study. Kacker R; Harisaran V; Given L; Miner M; Rittmaster R; Morgentaler A Andrologia; 2015 Mar; 47(2):148-52. PubMed ID: 24499051 [TBL] [Abstract][Full Text] [Related]
10. Effect of testosterone supplementation with and without a dual 5α-reductase inhibitor on fat-free mass in men with suppressed testosterone production: a randomized controlled trial. Bhasin S; Travison TG; Storer TW; Lakshman K; Kaushik M; Mazer NA; Ngyuen AH; Davda MN; Jara H; Aakil A; Anderson S; Knapp PE; Hanka S; Mohammed N; Daou P; Miciek R; Ulloor J; Zhang A; Brooks B; Orwoll K; Hede-Brierley L; Eder R; Elmi A; Bhasin G; Collins L; Singh R; Basaria S JAMA; 2012 Mar; 307(9):931-9. PubMed ID: 22396515 [TBL] [Abstract][Full Text] [Related]
11. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065 [TBL] [Abstract][Full Text] [Related]
12. Effects of androgen deficiency and replacement on prostate zonal volumes. Jin B; Conway AJ; Handelsman DJ Clin Endocrinol (Oxf); 2001 Apr; 54(4):437-45. PubMed ID: 11318778 [TBL] [Abstract][Full Text] [Related]
13. Effects of Testosterone Replacement Therapy on Lower Urinary Tract Symptoms: A Systematic Review and Meta-analysis. Kohn TP; Mata DA; Ramasamy R; Lipshultz LI Eur Urol; 2016 Jun; 69(6):1083-90. PubMed ID: 26874809 [TBL] [Abstract][Full Text] [Related]
14. Effect of testosterone replacement therapy on lower urinary tract symptoms: A systematic review and network meta-analysis. Yuan X; Xiong X; Xue J J Evid Based Med; 2024 Sep; 17(3):490-502. PubMed ID: 39004879 [TBL] [Abstract][Full Text] [Related]
15. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia. Bartsch G; Rittmaster RS; Klocker H World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710 [TBL] [Abstract][Full Text] [Related]
16. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis. Morlock R; Goodwin B; Gomez Rey G; Eaddy M Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026 [TBL] [Abstract][Full Text] [Related]
17. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia. Habib FK; Ross M; Tate R; Chisholm GD Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694 [TBL] [Abstract][Full Text] [Related]
18. The effect of testosterone replacement therapy on prostate-specific antigen (PSA) levels in men being treated for hypogonadism: a systematic review and meta-analysis. Kang DY; Li HJ Medicine (Baltimore); 2015 Jan; 94(3):e410. PubMed ID: 25621688 [TBL] [Abstract][Full Text] [Related]
19. Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity. Helfand BT; Blackwell RH; McVary KT J Urol; 2010 Jul; 184(1):218-23. PubMed ID: 20483154 [TBL] [Abstract][Full Text] [Related]
20. Benign prostatic hyperplasia progression and its impact on treatment. Djavan B; Waldert M; Ghawidel C; Marberger M Curr Opin Urol; 2004 Jan; 14(1):45-50. PubMed ID: 15091050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]